Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Assets (2018 - 2025)

Summit Therapeutics' Assets history spans 8 years, with the latest figure at $261.7 million for Q3 2025.

  • For Q3 2025, Assets fell 47.95% year-over-year to $261.7 million; the TTM value through Dec 2025 reached $94.0 million, down 78.41%, while the annual FY2024 figure was $435.6 million, 114.62% up from the prior year.
  • Assets reached $261.7 million in Q3 2025 per SMMT's latest filing, down from $324.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $664.2 million in Q4 2022 to a low of $95.7 million in Q2 2022.
  • Average Assets over 5 years is $257.9 million, with a median of $218.5 million recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 485.82% in 2022, then plummeted 69.44% in 2023.
  • A 5-year view of Assets shows it stood at $113.4 million in 2021, then surged by 485.82% to $664.2 million in 2022, then tumbled by 69.44% to $202.9 million in 2023, then surged by 114.62% to $435.6 million in 2024, then plummeted by 39.91% to $261.7 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Assets are $261.7 million (Q3 2025), $324.0 million (Q2 2025), and $383.8 million (Q1 2025).